The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients
Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.
humira
-
Read more: The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients -
Read more: 3 Challenges to Patents on Therapeutic Monoclonal Antibodies 3 Challenges to Patents on Therapeutic Monoclonal Antibodies
Three developments may have effects on the use of patents to fend off competition for therapeutic monoclonal antibodies.
-
Read more: When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims When “Pay-for-Delay” Becomes “Delay-Without-Pay”: Humira Antitrust Claims
In this post, I explore several problematic aspects of the court’s reasoning for rejecting the claims of pay-for-delay and market allocation.
-
Read more: AbbVie Wins First Round in Humira Antitrust Lawsuit AbbVie Wins First Round in Humira Antitrust Lawsuit
The purpose of the secondary patent filings was to assemble a thicket of patents, 132 in all, to prohibit competition from biosimilar companies.
